Display options
Cite
Castellanos JA, Merchant NB, Nagathihalli NS. Emerging targets in pancreatic cancer: epithelial-mesenchymal transition and cancer stem cells. Onco Targets Ther. 2013;6:1261-7doi: 10.2147/OTT.S34670.
Castellanos, J. A., Merchant, N. B., & Nagathihalli, N. S. (2013). Emerging targets in pancreatic cancer: epithelial-mesenchymal transition and cancer stem cells. OncoTargets and therapy, 61261-7. https://doi.org/10.2147/OTT.S34670
Castellanos, Jason A, et al. "Emerging targets in pancreatic cancer: epithelial-mesenchymal transition and cancer stem cells." OncoTargets and therapy vol. 6 (2013): 1261-7. doi: https://doi.org/10.2147/OTT.S34670
Castellanos JA, Merchant NB, Nagathihalli NS. Emerging targets in pancreatic cancer: epithelial-mesenchymal transition and cancer stem cells. Onco Targets Ther. 2013 Sep 13;6:1261-7. doi: 10.2147/OTT.S34670. PMID: 24049451; PMCID: PMC3775701.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2013 Sep 13;6:1261-7. doi: 10.2147/OTT.S34670.

Emerging targets in pancreatic cancer: epithelial-mesenchymal transition and cancer stem cells.

OncoTargets and therapy

Jason A Castellanos, Nipun B Merchant, Nagaraj S Nagathihalli

Affiliations

  1. Department of Surgery, Vanderbilt University School of Medicine, Nashville, TN, USA.

PMID: 24049451 PMCID: PMC3775701 DOI: 10.2147/OTT.S34670

Abstract

Pancreatic ductal adenocarcinoma is one of the most aggressive solid malignancies and is characterized by poor response to current therapy and a dismal survival rate. Recent insights regarding the role of cancer stem cells (CSCs) and epithelial-mesenchymal transition (EMT) in tumorigenesis have brought further understanding to the field and have highlighted new therapeutic targets. CSCs are a distinct subset of cancer cells, with the ability to differentiate into other cell types and self-renew in order to fuel the maintenance of tumor amplification. Transition of a cancer cell from an EMT leads to increased migratory and invasive properties, and thus facilitates initiation of metastasis. EMT is regulated by a complex network of factors that includes cytokines, growth factors, aberrant signaling pathways, transcription factors, and the tumor microenvironment. There is emerging evidence that the EMT process may give rise to CSCs, or at least cells with stem cell-like properties. We review the key pathways involved in both of these processes, the biomarkers used to identify CSCs, and new therapeutic approaches targeting CSCs and EMT in pancreatic ductal adenocarcinoma.

Keywords: cancer stem cells; epithelial-mesenchymal transition; pancreatic ductal adenocarcinoma; tumor microenvironment

References

  1. J Exp Med. 2007 Nov 26;204(12):2935-48 - PubMed
  2. Nat Med. 2011 Mar;17(3):313-9 - PubMed
  3. Cancer Res. 2006 Oct 1;66(19):9339-44 - PubMed
  4. Clin Cancer Res. 2007 Aug 15;13(16):4769-76 - PubMed
  5. Cancer Res. 2007 Oct 1;67(19):9066-76 - PubMed
  6. CA Cancer J Clin. 2013 Jan;63(1):11-30 - PubMed
  7. Cell Stem Cell. 2011 Nov 4;9(5):433-46 - PubMed
  8. Cancer Cell. 2012 Dec 11;22(6):709-24 - PubMed
  9. Cancer Cell. 2009 Mar 3;15(3):207-19 - PubMed
  10. Cell. 2008 May 16;133(4):704-15 - PubMed
  11. Cell. 1990 Jan 12;60(1):45-52 - PubMed
  12. J Gastroenterol Hepatol. 2012 Mar;27 Suppl 2:15-8 - PubMed
  13. Kidney Int. 2009 Jun;75(12):1278-1287 - PubMed
  14. Nat Rev Cancer. 2007 Jun;7(6):415-28 - PubMed
  15. Cancer Lett. 2013 Sep 10;338(1):94-100 - PubMed
  16. Int J Biochem Cell Biol. 2005 Apr;37(4):715-9 - PubMed
  17. Cancer Res. 2007 Mar 1;67(5):2187-96 - PubMed
  18. Br J Cancer. 2008 Apr 22;98(8):1389-97 - PubMed
  19. Gastroenterology. 2009 Jul;137(1):361-71, 371.e1-5 - PubMed
  20. Cell. 2005 Jun 17;121(6):823-35 - PubMed
  21. Cancer Cell. 2011 Apr 12;19(4):498-511 - PubMed
  22. Oncogene. 2004 Jul 29;23(34):5748-58 - PubMed
  23. Clin Exp Metastasis. 2009;26(7):611-23 - PubMed
  24. Blood. 1997 May 1;89(9):3385-95 - PubMed
  25. Gastroenterology. 2011 Dec;141(6):2218-2227.e5 - PubMed
  26. Stem Cells. 2009 Oct;27(10):2383-92 - PubMed
  27. Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3983-8 - PubMed
  28. Nat Rev Cancer. 2012 Jan 24;12(2):89-103 - PubMed
  29. Oncol Rep. 2010 Jun;23(6):1545-52 - PubMed
  30. Cancer Res. 2003 Sep 15;63(18):5821-8 - PubMed
  31. Am J Pathol. 2010 Nov;177(5):2585-96 - PubMed
  32. Gastroenterology. 2007 Jun;132(7):2542-56 - PubMed
  33. PLoS One. 2011;6(6):e20636 - PubMed
  34. Cancer Res. 2005 May 15;65(10):4320-33 - PubMed
  35. Nat Med. 2011 Aug 28;17(9):1086-93 - PubMed
  36. EMBO J. 2011 Feb 16;30(4):770-82 - PubMed
  37. Cancer Cell. 2013 Jun 10;23(6):839-52 - PubMed
  38. J Natl Cancer Inst. 2010 Mar 3;102(5):340-51 - PubMed
  39. Cancer. 1990 Jul 1;66(1):56-61 - PubMed
  40. JOP. 2007 Jan 09;8(1 Suppl):132-40 - PubMed
  41. J Cell Physiol. 2007 Nov;213(2):374-83 - PubMed
  42. Biochem Biophys Res Commun. 1998 Feb 13;243(2):503-8 - PubMed
  43. Clin Gastroenterol Hepatol. 2009 Nov;7(11 Suppl):S48-54 - PubMed
  44. Cancer Cell. 2011 Nov 15;20(5):576-90 - PubMed
  45. Nat Cell Biol. 2009 Dec;11(12):1487-95 - PubMed
  46. Mol Cancer Ther. 2012 Sep;11(9):1999-2009 - PubMed
  47. Clin Cancer Res. 2011 Oct 1;17(19):6174-84 - PubMed
  48. Nature. 2003 Oct 23;425(6960):851-6 - PubMed
  49. Gastroenterology. 2005 Apr;128(4):907-21 - PubMed
  50. Jpn J Clin Oncol. 2005 Jun;35(6):342-8 - PubMed
  51. FASEB J. 2007 Dec;21(14):3777-85 - PubMed
  52. J Clin Oncol. 2008 Jun 10;26(17):2806-12 - PubMed
  53. Oncogene. 2011 May 5;30(18):2123-34 - PubMed
  54. Cell Cycle. 2012 Apr 1;11(7):1282-90 - PubMed
  55. Int J Cancer. 2008 Jun 15;122(12):2707-18 - PubMed
  56. Cell Stem Cell. 2007 Sep 13;1(3):313-23 - PubMed
  57. Cancer Res. 2007 Apr 1;67(7):3153-61 - PubMed
  58. Cancer Cell. 2012 Dec 11;22(6):725-36 - PubMed
  59. Am J Physiol Gastrointest Liver Physiol. 2008 Oct;295(4):G709-17 - PubMed
  60. Front Biosci (Landmark Ed). 2012 Jun 01;17:2059-69 - PubMed
  61. J Biol Chem. 1999 Mar 5;274(10):6499-506 - PubMed
  62. Cell Cycle. 2010 Jun 15;9(12):2363-74 - PubMed
  63. Genes Dev. 2006 Nov 15;20(22):3130-46 - PubMed
  64. Mol Cancer Ther. 2010 Aug;9(8):2322-32 - PubMed
  65. Cell. 2012 Jan 20;148(1-2):349-61 - PubMed
  66. Cell. 2000 Jan 7;100(1):57-70 - PubMed
  67. Clin Cancer Res. 2011 Feb 1;17(3):483-93 - PubMed
  68. Front Oncol. 2013 Jan 04;2:209 - PubMed
  69. Cell Cycle. 2005 Jun;4(6):772-6 - PubMed
  70. J Cell Biol. 1994 Apr;125(2):437-46 - PubMed
  71. Nature. 2007 Jan 4;445(7123):106-10 - PubMed
  72. Gastroenterology. 2013 Jun;144(6):1241-8 - PubMed
  73. Blood. 2002 Jan 1;99(1):319-25 - PubMed
  74. J Surg Res. 2007 Aug;141(2):196-203 - PubMed
  75. Cancer Res. 2007 Feb 1;67(3):1030-7 - PubMed
  76. EMBO Mol Med. 2009 Sep;1(6-7):338-51 - PubMed
  77. Gut. 2012 Feb;61(2):172-8 - PubMed
  78. Am J Pathol. 2008 Apr;172(4):926-39 - PubMed
  79. Gastroenterology. 2009 Sep;137(3):1102-13 - PubMed

Publication Types

Grant support